TGF-beta is a cytokine thought to function as a tumor promoter in advanced malignancies. In this setting, TGF-beta increases cancer cell proliferation, survival, and migration, and orchestrates complex, pro-tumorigenic changes in the tumor microenvironment. Here, we find that in melanoma, integrin beta1-mediated TGF-beta activation may also produce tumor suppression via an altered host response. In the A375 human melanoma cell nu/nu xenograft model, we demonstrate that cell surface integrin beta1-activation increases TGF-beta activity, resulting in stromal activation, neo-angiogenesis and, unexpectedly for this nude mouse model, increase in the number of intra-tumoral CD8+ T lymphocytes within the tumor microenvironment. This is associated with attenuation of tumor growth and long-term survival benefit. Correspondingly, in human melanomas, TGF-beta1 correlates with integrin beta1/TGF-beta1 activation and the expression of markers for vasculature and stromal activation. Surprisingly, this integrin beta1/TGF-beta1 transcriptional footprint also correlates with the expression of markers for tumor-infiltrating lymphocytes, multiple immune checkpoints and regulatory pathways, and, importantly, better long-term survival of patients. These correlations are unique to melanoma, in that we do not observe similar associations between beta1 integrin/TGF-beta1 activation and better long-term survival in other human tumor types. These results suggest that activation of TGF-beta1 in melanoma may be associated with the generation of an anti-tumor host response that warrants further study.